These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2197817)

  • 41. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Akhtar M; Breithardt G; Camm AJ; Coumel P; Janse MJ; Lazzara R; Myerburg RJ; Schwartz PJ; Waldo AL; Wellens HJ
    Circulation; 1990 Mar; 81(3):1123-7. PubMed ID: 1689621
    [No Abstract]   [Full Text] [Related]  

  • 42. Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia.
    Wyndham CR; Pratt CM; Mann DE; Winkle RA; Somberg J; de Maria AN; Josephson ME
    Am J Cardiol; 1987 Oct; 60(11):67F-72F. PubMed ID: 3310588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons from the cardiac arrhythmia suppression trial.
    Garratt C; Ward DE; Camm AJ
    BMJ; 1989 Sep; 299(6703):805-6. PubMed ID: 2510839
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacokinetics of moricizine HCl.
    Woosley RL; Morganroth J; Fogoros RN; McMahon FG; Humphries JO; Mason DT; Williams RL
    Am J Cardiol; 1987 Oct; 60(11):35F-39F. PubMed ID: 3310583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overview: moricizine--can it meet the challenge?
    Morganroth J; Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):1D-2D; discussion 68D-71D. PubMed ID: 2407086
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacology and clinical use of a new group of antiarrhythmic drugs: derivatives of tricyclic nitrogen-containing systems.
    Kaverina NV; Sokolov SF
    Pharmacol Res; 1992 Apr; 25(3):217-25. PubMed ID: 1518765
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ethmozine (moricizine HCl): a promising drug for "automatic" atrial ectopic tachycardia.
    Evans VL; Garson A; Smith RT; Moak JP; McVey P; McNamara DG
    Am J Cardiol; 1987 Oct; 60(11):83F-86F. PubMed ID: 3310591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: documentation of efficacy and long-term safety.
    Pratt CM; Yepsen SC; Taylor AA; Mason DT; Miller RR; Quinones MA; Lewis RA
    Am Heart J; 1983 Jul; 106(1 Pt 1):85-91. PubMed ID: 6346845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The pharmacology of the new combined anti-arrhythmia preparation metatsizin].
    Kaverina NV; Chichkanov GG; Bugriĭ EM; Vititnova MB; Tolmacheva EA; Turilova AI; Kryzhanovskiĭ SA; Lyskovtsev VV; Rodionov AP; Beloborodov VL
    Eksp Klin Farmakol; 1998; 61(2):33-6. PubMed ID: 9621171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and risks of moricizine in inducible sustained ventricular tachycardia.
    Damle R; Levine J; Matos J; Greenberg S; Brooks R; Frumkin W; Goldberger J; Kadish AH
    Ann Intern Med; 1992 Mar; 116(5):375-81. PubMed ID: 1736770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1990 Mar; 11(3):194-9. PubMed ID: 2108031
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: results of a prospective, controlled trial.
    Singh SN; DiBianco R; Gottdiener JS; Ginsberg R; Fletcher RD
    Am J Cardiol; 1984 Mar; 53(6):745-50. PubMed ID: 6367416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New antiarrhythmic drugs.
    Nestico PF; Morganroth J; Horowitz LN
    Drugs; 1988 Mar; 35(3):286-319. PubMed ID: 3286214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The antiarrhythmic drug Etmozine in the light of new findings].
    Mádle A
    Vnitr Lek; 1987 Sep; 33(9):810-5. PubMed ID: 3314125
    [No Abstract]   [Full Text] [Related]  

  • 56. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
    Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW
    J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum digoxin concentrations during ethmozine antiarrhythmic therapy.
    Kennedy HL; Sprague MK; Redd RM; Wiens RD; Blum RI; Buckingham TA
    Am Heart J; 1986 Apr; 111(4):667-72. PubMed ID: 2420164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
    Akiyama T; Pawitan Y; Campbell WB; Papa L; Barker AH; Rubbert P; Friedman L; Keller M; Josephson RA
    J Am Geriatr Soc; 1992 Jul; 40(7):666-72. PubMed ID: 1607582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
    J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.